4-氨基-2-环丙基-5-嘧啶甲腈 | 23662-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氨基-2-环丙基-5-嘧啶甲腈
• 中文别名: 5-嘧啶甲腈,4-氨基-2-环丙基-
• 英文名称: 5-Cyano-4-amino-2-cyclopropylpyrimidin
• 英文别名: 4-amino-2-cyclopropyl-pyrimidine-5-carbonitrile；4-Amino-2-cyclopropylpyrimidine-5-carbonitrile
• CAS: 23662-47-7
• 化学式: C₈H₈N₄
• mdl: MFCD11054237
• 分子量: 160.178
• InChiKey: IQZSBEYDPXQSNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  丙二腈 、 4-氨基-2-环丙基-5-嘧啶甲腈 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 生成 5,7-Diamino-2-cyclopropylpyrido[2,3-d]pyrimidine-6-carbonitrile
  参考文献：
  名称：

  Negishi cross-coupling enabled synthesis of novel NAD+-dependent DNA ligase inhibitors and SAR development

  摘要：

  Two novel compounds, pyridopyrimidines (1) and naphthyridines (2) were identified as potent inhibitors of bacterial NAD(+)-dependent DNA ligase (Lig) A in a fragment screening. SAR was guided by molecular modeling and X-ray crystallography. It was observed that the diaminonitrile pharmacophore made a key interaction with the ligase enzyme, specifically residues Glu114, Lys291, and Leu117. Synthetic challenges limited opportunities for diversification of the naphthyridine core, therefore most of the SAR was focused on a pyridopyrimidine scaffold. The initial diversification at R-1 improved both enzyme and cell potency. Further SAR developed at the R-2 position using the Negishi cross-coupling reaction provided several compounds, among these compounds 22g showed good enzyme potency and cellular potency. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.075
• 作为产物：
  描述：

  环丙甲脒盐酸盐 、 乙氧基亚甲基丙二腈 在 乙醇 、 sodium 作用下， 反应 2.0h， 生成 4-氨基-2-环丙基-5-嘧啶甲腈
  参考文献：
  名称：

  Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives

  摘要：

  A series of 51 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat. A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyrido[2,3-d]pyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg. Normalized blood pressure levels could then be maintained by single daily oral doses. The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

  DOI：

  10.1021/jm00136a006

文献信息

• CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD.

  公开号：US20160122319A1

  公开（公告）日：2016-05-05

  The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine D 4 receptors, which are useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, a compound of formula (1) or a pharmaceutically acceptable salt thereof is provided, wherein n and m are independently 1 or 2; R a is C 1-6 alkyl group, C 3-6 cycloalkyl group, or amino group; R b is hydrogen atom, C 1-6 alkyl group or the like, provided that when R a is amino group, then R b is hydrogen atom; R c1 and R c2 are independently hydrogen atom, or C 1-6 alkyl group; R d1 and R d2 are independently hydrogen atom, fluorine atom or the like; ring Q is an optionally-substituted pyridyl group or an optionally-substituted isoquinolyl group; and the bond having a dashed line is a single or double bond.

  本发明提供了一种对多巴胺D4受体具有高选择性的环状氨基甲基嘧啶衍生物及其药用盐，可用于治疗注意力缺陷多动症等疾病。具体提供了一种公式(1)的化合物或其药用盐，其中n和m独立为1或2；Ra为C1-6烷基、C3-6环烷基或氨基；Rb为氢原子、C1-6烷基等，条件是当Ra为氨基时，Rb为氢原子；Rc1和Rc2独立为氢原子或C1-6烷基；Rd1和Rd2独立为氢原子、氟原子等；环Q为可选取代的吡啶基或可选取代的异喹啉基；且虚线表示的键为单键或双键。
• US9732065B2
  申请人：——

  公开号：US9732065B2

  公开（公告）日：2017-08-15
• [EN] CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE<br/>[FR] DÉRIVÉ CYCLIQUE D'AMINOMÉTHYL PYRIMIDINE
  申请人：SUMITOMO DAINIPPON PHARMA CO LTD

  公开号：WO2014192868A1

  公开（公告）日：2014-12-04

  　本発明は、ドパミンＤ４受容体に対して選択性の高い作用を示し、注意欠陥多動性障害等の治療剤として有用な環状アミノメチルピリミジン誘導体及びその薬学上許容される塩を提供する。具体的には、式（１）で表される化合物またはその薬学上許容される塩を提供する。 ［式中、ｎおよびｍは、それぞれ独立して、１または２を表し；Ｒａは、Ｃ１－６アルキル基、Ｃ３－６シクロアルキル基、またはアミノ基を表し；Ｒｂは、水素原子、Ｃ１－６アルキル基等を表し（ただし、Ｒａがアミノ基のときは、Ｒｂは水素原子である。）；Ｒｃ１およびＲｃ２は、それぞれ独立して、水素原子、またはＣ１－６アルキル基を表し；Ｒｄ１およびＲｄ２は、それぞれ独立して、水素原子、フッ素原子等を表し；環Ｑは、置換されていてもよいピリジル基、または置換されていてもよいイソキノリニル基を表し；破線を含む結合は単結合または二重結合を表す。]